利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.03 秒)

    Pharmaceutical compositions comprising S-(−)-N-propargyl-1-aminoindan
    4.
    发明授权
    Pharmaceutical compositions comprising S-(−)-N-propargyl-1-aminoindan 有权
    包含S - （ - ） - N-炔丙基-1-氨基茚满的药物组合物

    公开(公告)号：US06277886B1

    公开(公告)日：2001-08-21

    申请号：US09228153

    申请日：1999-01-11

    申请人： Ruth Levy ,  Moussa B. H. Youdim ,  John P. M. Finberg ,  Sasson Cohen ,  Jeff Sterling

    发明人： Ruth Levy ,  Moussa B. H. Youdim ,  John P. M. Finberg ,  Sasson Cohen ,  Jeff Sterling

    IPC分类号： A61K31135

    CPC分类号： C07C211/42 ,  A61K31/135 ,  C07C2602/08 ,  Y10S514/878 ,  Y10S514/879 ,  Y10S514/903

    摘要： Pharmaceutical compositions for the treatment of a neurological disorder of neurotrauma or for improving memory in a patient comprising a therapeutically effective amount of S-(−)-N-proparygl-1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. The pharmaceutical compositions are adapted, in particular for treating a neurological hypoxia or anoxia, neurodegenerative diseases. Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage.

    摘要翻译： 用于治疗神经损伤神经障碍或改善患者记忆力的药物组合物，其包含治疗有效量的S-（ - ） - N-丙酰基-1-氨基茚满或其药学上可接受的盐作为活性成分，和药学上可接受的盐 主动载体。 药物组合物特别适用于治疗神经缺氧或缺氧，神经变性疾病。 帕金森病，阿尔茨海默氏病，神经毒性损伤，头部创伤损伤，脊髓损伤或任何其他形式的神经损伤。

    Antiarrhythmic quinuclidine carboxylic acid xylidide and method of producing the same and similar compounds
    7.
    发明授权
    Antiarrhythmic quinuclidine carboxylic acid xylidide and method of producing the same and similar compounds 失效
    抗坏血酸喹喔啉羧酸酰亚胺及其制备方法及类似化合物

    公开(公告)号：US4146628A

    公开(公告)日：1979-03-27

    申请号：US821748

    申请日：1977-08-04

    申请人： Edna Oppenheimer ,  Eliezer Kaplinsky ,  Sasson Cohen

    发明人： Edna Oppenheimer ,  Eliezer Kaplinsky ,  Sasson Cohen

    IPC分类号： A61K31/445

    CPC分类号： A61K31/445 ,  Y10S514/821

    摘要： The invention relates to the compound 2-6-xylidide of quinuclidine-3-carboxylic acid and its pharmaceutically acceptable salts, such as the hydrochloride, which have been found to be effective antiarrhythmic agents. The invention further relates to the production of this antiarrhythmic compound which method is applicable also to the production of related compounds which, however, do not have antiarrhythmic action, e.g. the quinuclidine-2-carboxylic acid xylidides. The compounds are produced according to this method by reacting the quinuclidine carboxylic acid in anhydrous chloroform and oxalyl chloride with the dimethylaniline. The desired compound is produced in high yield with a high degree of purity.